التفاصيل البيبلوغرافية
العنوان: [Untitled]
المساهمون: Jonkers, J.M.M., Rottenberg, S., Irth, H., Bouwstra, J.A., Attikum, H. van, Noordermeer, S.M., Vugt, M. van, Leiden University
سنة النشر: 2021
مصطلحات موضوعية: Breast cancer, PARP inhibitor, DNA end resection, HR deficient, SHLD complex, Drug resistance, Genetically engineered mouse model, 53BP1 pathway, CST complex, BRCA1
الوصف: The clinical potential of applying synthetic lethality to cancer treatment is famously demonstrated by the BRCA1/PARP1 paradigm: a tumor specific defect in BRCA1 – a component of the DNA double-strand break (DSB) repair pathway homologous recombination (HR) – results in a remarkable sensitivity to PARP1 inhibition (PARPi). Despite spectacular initial responses in patients, resistance to PARPi treatment may develop and must be overcome to maximally exploit this interaction in the clinic. Genetically engineered (mouse) model systems have shown that PARPi resistance may arise through inactivation of the 53BP1 pathway. The 53BP1 pathway normally protects DSB ends from resection and the removal of this “brake” restores HR in the absence of BRCA1. However, how the 53BP1 pathway protects DSB ends from resection has remained elusive. In this thesis, advances in 3D tumor organoid culture protocols and CRISPR/Cas9 (screening) technology were applied to identify and validate new components of the 53BP1 pathway that render BRCA1 deficient cells resistant to PARPi upon their loss. Furthermore, a new acquired vulnerability that can be therapeutically exploited to deplete such PARPi resistant cells is described. Together, this thesis provides mechanistic insight in DSB repair and illustrates how such fundamental knowledge may stand at the basis to combat resistance.
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______202::2866891b9b6875b365358b3797c884f3
Rights: OPEN
رقم الانضمام: edsair.od.......202..2866891b9b6875b365358b3797c884f3
قاعدة البيانات: OpenAIRE